This compound, (3R,4R,5R)-3-(1-Ethylpropoxy)-4-hydroxy-5-[(methylsulfonyloxy)]-1-cyclohexen-1-carboxylic acid ethyl ester, is a key chemical entity in the pharmaceutical industry. It is specifically identified as a process-related impurity of Oseltamivir, the active pharmaceutical ingredient in the antiviral medication Tamiflu®. Its chemical structure is closely related to the final API, differing in the substitution pattern on the cyclohexene ring. As an Oseltamivir impurity, its primary application is in analytical quality control and regulatory compliance. It serves as a certified reference standard (impurity standard) used in high-performance liquid chromatography (HPLC) and other analytical methods to monitor, identify, and quantify this specific impurity during the manufacturing process of Oseltamivir phosphate. This ensures the final drug product meets stringent purity and safety specifications set by pharmacopoeias like USP, EP, and ICH guidelines. The synthesis and characterization of this impurity are crucial for process chemistry development and optimization. By studying its formation and behavior, manufacturers can refine the synthesis route of Oseltamivir to minimize the generation of this and related impurities, thereby improving the overall yield, purity, and efficiency of the API production.